Join the Melanoma - Metastatic group to help and get support from people like you.
Melanoma - Metastatic News (Page 2)
Anti-CTAg Antibodies Identified in Stage I, II Melanoma
WEDNESDAY, Oct. 2, 2024 – Circulating antibodies against cancer-testis antigens (CTAgs) are found in stage I and stage II melanoma plasma samples, according to a study presented at the annual...
Melanoma Risk Increased After Radioactive Iodine Treatment for Primary Thyroid Cancer
THURSDAY, Sept. 26, 2024 – Patients with primary thyroid cancer who receive radioactive iodine therapy have an elevated risk for melanoma and other nonkeratinocyte skin cancers when limiting the...
Long-Term Survival Benefit Seen for Nivolumab in Advanced Melanoma
THURSDAY, Sept. 19, 2024 – For patients with advanced melanoma, there is a survival benefit for nivolumab plus ipilimumab and for nivolumab monotherapy compared with ipilimumab monotherapy,...
Study Looks at Sex Differences in Melanoma Incidence
TUESDAY, Sept. 17, 2024 – Melanoma rates differ for men and women, including in terms of ages of occurrence and locations of melanoma, according to a study published online June 17 in the Journal of...
Immunotherapy Drugs Extend Survival for Patients With Advanced Melanomas
MONDAY, Sept 16, 2024 – A decade of patient follow-up finds a combo of two immunotherapy drugs can greatly extend survival for people with advanced melanomas. In 2011, a diagnosis of advanced,...
Melanoma Incidence, Mortality Declining in Those Aged 30 to 49 Years
TUESDAY, Sept. 10, 2024 – For adults aged 30 to 49 years, there has been a decline in melanoma incidence and mortality, according to a study published online Sept. 8 in JAMA Dermatology to coincide...
Gene Expression Signature Predicts Immune-Related Adverse Events in Melanoma Patients
MONDAY, Aug. 12, 2024 – A gene expression signature in peripheral CD4+ T-cells can predict severe immune-related adverse events (irAEs) among melanoma patients treated with ipilimumab/nivolumab,...
Prevalence of Skin Cancer Varies for Sexual Minority, Heterosexual Adults
FRIDAY, July 19, 2024 – With respect to their lifetime prevalence of skin cancer, sexual minority (SM) adults differ across racial and ethnic groups and among males and females, according to a study...
Rural Residents Continue to Have Higher Odds of Skin Cancer
TUESDAY, July 9, 2024 – Urban-rural disparities in skin cancer prevalence continue to persist, according to a study published in the June issue of the Journal of Drugs in Dermatology. Rachel R. Lin, ...
FDA Grants Accelerated Approval for Amtagvi (lifileucel) for the Treatment of Advanced Melanoma
SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) – Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor...
FDA Approves Opdualag (nivolumab and relatlimab-rmbw) for the Treatment of Patients with Unresectable or Metastatic Melanoma
PRINCETON, N.J.--(BUSINESS WIRE)-- March 18, 2022 – Bristol Myers Squibb (NYSE: BMY) today announced that Opdualag (nivolumab and relatlimab-rmbw),anew, first-in-class,fixed-dose combination of...
FDA Approves Keytruda (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
KENILWORTH, N.J.--(BUSINESS WIRE) February 19, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Mektovi (binimetinib) and Braftovi (encorafenib) in Combination for Unresectable or Metastatic Melanoma with BRAF Mutations
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib (Braftovi and Mektovi, Array BioPharma Inc.) in combination for patients with unresectable or metastatic...
Array BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresectable or Metastatic Melanoma with BRAF Mutations
BOULDER, Colo., June 27, 2018 /PRNewswire/ – Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi capsules in combination with...
Bristol-Myers Squibb’s Opdivo (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing
PRINCETON, N.J.--(BUSINESS WIRE) March 6, 2018 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License...